The study shows that Mursla Bio's method yields robust, organ-specific multi-omics data using minimal blood volume, offering a novel scalable approach for biomarker and AI development.

Blood of my Blood focuses on Jamie and Claire’s parents, and the trailer shows how the couples might have met.

CAMBRIDGE, Mass. & SINGAPORE, July 11, 2024--Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and ...

Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of significant oncology therapies for physicians and their patients.

Carlsbad, CA, Jan. 29, 2025-- Palisade Bio, Inc., a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune ...

Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by ...

Sunbird Bio has unveiled new data demonstrating that its diagnostic technology classified Parkinson’s disease-positive blood samples with 86% accuracy through the direct detection of aggregated ...

Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of moderate-to-severe chronic graft versus host disease (GvHD). The Phase ...

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 Sep. 25, 2024 4:30 PM ET Cabaletta Bio, Inc. (CABA) ...

SEOUL, South Korea, Sept. 15, 2022 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' at the 2022 edition of the ...

The poster, entitled: Duvelisib in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma: Final Results from the Phase 2 PRIMO Trial highlights the outcomes of 123 patients in the PRIMO ...

SEOUL, South Korea, Sept. 15, 2022 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' at the 2022 edition of the ...